|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
9 p, 1.5 MB |
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non-small cell lung cancer in Spain
/
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Álvarez, Rosa (Hospital Gregorio Marañón (Madrid)) ;
Ortega, Ana Laura (Hospital Universitario de Jaén) ;
de Alda, Lucía Ruiz (Roche Farma) ;
Gordo, Rocío (Roche Farma) ;
García, J.Francisco (Roche Farma) ;
Ivanova-Markova, Yoana (Weber) ;
González-Domínguez, Almudena (Weber) ;
San Cristóbal, Raquel Sánchez (Weber) ;
Rojo, Federico (Hospital Universitario Fundación Jiménez Díaz) ;
Universitat Autònoma de Barcelona
In recent years, target therapies to specific molecular alterations in advanced non-small cell lung cancer (NSCLC) have been identified and have shown superior efficacy compared to non-targeted treatments. [...]
2022 - 10.33393/GRHTA.2022.2449
Global and Regional Health Technology Assessment, Vol. 9 (january 2022) , p. 82-90
|
|
|
3.
|
|
14 p, 563.4 KB |
Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors : The necessity of repeated molecular analysis
/
González-Larriba, José Luis (Hospital Universitario Clínico San Carlos (Madrid)) ;
Lázaro-Quintela, Martín (Complexo Hospitalario Universitario de Vigo) ;
Cobo, Manuel (Hospital Regional Universitario de Málaga) ;
Dómine, Manuel (Hospital Universitario Fundación Jiménez Díaz) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
García-Campelo, Rosario (Complejo Hospitalario Universitario de A Coruña) ;
Universitat Autònoma de Barcelona
One of the most important advances in the treatment of non-small cell lung cancer (NSCLC) has been the identification of molecular alterations vulnerable to targeted inhibition, such as mutations in the epidermal growth factor receptor (EGFR) gene. [...]
2017 - 10.21037/tlcr.2017.10.03
Translational Lung Cancer Research, Vol. 6 (january 2017) , p. S21-S34
|
|
|
4.
|
|
11 p, 474.2 KB |
Phase 1/2 Study of the CD56-Targeting Antibody-Drug Conjugate Lorvotuzumab Mertansine (IMGN901) in Combination With Carboplatin/Etoposide in Small-Cell Lung Cancer Patients With Extensive-Stage Disease
/
Socinski, Mark A. (Univeristy of Pittsburgh Cancer Institute) ;
Kaye, Frederic J. (University of Florida College of Medicine) ;
Spigel, David R. (Sarah Cannon Research Institute) ;
Kudrik, Fred J. (South Carolina Oncology Associates) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Ellis, Peter M. (Juravinski Cancer Centre) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Lorigan, Paul (University of Manchester/Christie NHS Foundation Trust) ;
Gandhi, Leena (Dana-Farber Cancer Institute (Boston, Estats Units d'Amèrica)) ;
Gutierrez, Martin E. (Holy Cross Hospital) ;
Nepert, Dale (Clinical Development. ImmunoGen Inc) ;
Corral, Jesus (Hospital 12 de Octubre (Madrid)) ;
Ares, Luis Paz (Hospital 12 de Octubre (Madrid)) ;
Universitat Autònoma de Barcelona
Lorvotuzumab mertansine (LM, IMGN901) is a CD56-targeting antibody-drug conjugate developed for tumor-selective delivery of the cytotoxic maytansinoid DM1. This phase 1/2 study evaluated the combination of LM with first-line carboplatin/etoposide chemotherapy in patients with extensive-disease small-cell lung cancer. [...]
2017 - 10.1016/j.cllc.2016.09.002
Clinical Lung Cancer, Vol. 18 Núm. 1 (january 2017) , p. 68-76.e2
|
|
|
5.
|
|
10 p, 666.8 KB |
Clinical management and outcome of patients with advanced NSCLC carrying EGFR mutations in Spain
/
Arriola, Edurne (Hospital del Mar (Barcelona, Catalunya)) ;
García Gómez, Ramón (Hospital General Universitario Gregorio Marañón) ;
Diz Taín, Pilar (Hospital Universitario de León) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Martínez Aguillo, Maite (Complejo Hospitalario de Navarra) ;
Valdivia, Javier (Hospital Universitario Virgen de las Nieves (Granada)) ;
Paredes, Alfredo (Hospital de Donostia (Sant Sebastià, País Basc)) ;
Sánchez-Torres, José Miguel (Hospital Universitario de la Princesa (Madrid)) ;
Peralta Muñoz, Sergio (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barneto Aranda, Isidoro (Hospital Universitario Reina Sofía (Córdoba, Espanya)) ;
Gutierrez, Vanesa (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Andrade Santiago, Jesús Manuel (Hospital Virgen de la Salud (Toledo)) ;
Aparisi, Francisco (Hospital Virgen de los Lirios) ;
Isla, Dolores (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Ponce, Santiago (Hospital 12 de Octubre (Madrid)) ;
Vicente Baz, David (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Artal, Ángel (Hospital Universitario Miguel Servet (Saragossa)) ;
Amador, Mariluz (AstraZeneca) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Universitat Autònoma de Barcelona
Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine-kinase inhibitors (TKIs) over chemotherapy has been demonstrated in several clinical trials, data from clinical practice is lacking and the optimal EGFR TKI to be used remains unclear. [...]
2018 - 10.1186/s12885-018-4004-7
BMC Cancer, Vol. 18 Núm. 1 (30 2018) , p. 106
|
|
|
6.
|
|
14 p, 1019.0 KB |
An exploratory, large-scale study of pain and quality of life outcomes in cancer patients with moderate or severe pain, and variables predicting improvement
/
Maximiano, Constanza (Hospital Puerta de Hierro de Majadahonda) ;
López, Iker (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Martín-Lorente, Cristina (Hospital de la Santa Creu i Sant Pau (Barcelona, Catalunya)) ;
Zugazabeitia, Luis (Hospital Povisa) ;
Martí-Ciriquián, Juan L. (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Núñez, Miguel A. (Hospital Santa María Nai) ;
Contreras, Jorge (Complejo Hospitalario Regional Carlos Haya) ;
Herdman, Michael (Insight Consulting and Research) ;
Traseira, Susana (Mundipharma Pharmaceuticals S.L.) ;
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Universitat Autònoma de Barcelona
There have been few large-scale, real world studies in Spain to assess change in pain and quality of life (QOL) outcomes in cancer patients with moderate to severe pain. This study aimed to assess changes on both outcomes after 3 months of usual care and to investigate factors associated with change in QoL. [...]
2018 - 10.1371/journal.pone.0193233
PloS one, Vol. 13 Núm. 4 (april 2018) , p. e0193233
|
|
|
7.
|
|
13 p, 828.8 KB |
Prospective detection of mutations in cerebrospinal fluid, pleural effusion, and ascites of advanced cancer patients to guide treatment decisions
/
Villatoro, Sergi (Grup Quirónsalud (Barcelona, Catalunya)) ;
Mayo-de-las-Casas, Clara (Grup Quirónsalud (Barcelona, Catalunya)) ;
Jordana-Ariza, Núria (Grup Quirónsalud (Barcelona, Catalunya)) ;
Viteri-Ramírez, Santiago (Grup Quirónsalud (Barcelona, Catalunya)) ;
Garzón-Ibañez, Mónica (Grup Quirónsalud (Barcelona, Catalunya)) ;
Moya-Horno, Irene (Hospital General de Catalunya) ;
García-Peláez, Beatrtiz (Grup Quirónsalud (Barcelona, Catalunya)) ;
González-Cao, María (Grup Quirónsalud (Barcelona, Catalunya)) ;
Malapelle, Umberto (University of Naples Federico II) ;
Balada-Bel, Ariadna (Grup Quirónsalud (Barcelona, Catalunya)) ;
Martínez-Bueno, Alejandro (Grup Quirónsalud (Barcelona, Catalunya)) ;
Campos, Raquel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Reguart, Noemi (Hospital Clínic i Provincial de Barcelona) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Blanco, Remei (Hospital Universitari MútuaTerrassa (Terrassa, Catalunya)) ;
Blasco, Ana (Hospital General Universitari de València) ;
Catalán, María J. (Grup Quirónsalud (Barcelona, Catalunya)) ;
González, Xavier (Hospital General de Catalunya) ;
Troncone, Giancarlo (University of Naples Federico II) ;
Karachaliou, Niki (Hospital del Sagrat Cor (Barcelona, Catalunya)) ;
Rosell, Rafael (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Molina-Vila, Miguel Ángel (Grup Quirónsalud (Barcelona, Catalunya)) ;
Universitat Autònoma de Barcelona
Many advanced cases of cancer show central nervous system, pleural, or peritoneal involvement. In this study, we prospectively analyzed if cerebrospinal fluid (CSF), pleural effusion (PE), and/or ascites (ASC) can be used to detect driver mutations and guide treatment decisions. [...]
2019 - 10.1002/1878-0261.12574
Molecular Oncology, Vol. 13 Núm. 12 (january 2019) , p. 2633-2645
|
|
|
8.
|
|
11 p, 639.3 KB |
Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients : the SOLID study
/
Provencio, Mariano (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Rodríguez-Abreu, Delvys (Hospital Universitario Insular de Gran Canaria) ;
Ortega Granados, Ana Laura (Hospital Universitario de Jaén) ;
Serrano, Gloria (Hospital Universiario Infanta Leonor (Madrid)) ;
Aguado, Carlos (Hospital Clínico San Carlos (Madrid)) ;
Franco, Fernando (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Gutierrez, Vanesa (Hospital Universitario Regional de Málaga) ;
López-Vivanco, Guillermo (Hospital Universitario Cruces (Barakaldo, País Basc)) ;
Guirado Risueño, María (Hospital General Universitario de Elche) ;
Benítez, Gretel (Hospital Universitario Insular de Gran Canaria) ;
Estival, Anna (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Calvo, Virginia (Hospital Universitario Puerta de Hierro Majadahonda) ;
Jiménez, Beatriz (Hospital Universitario HM Sanchinarro) ;
Arasanz, Hugo (Complejo Hospitalario Navarra-Navarrabiomeed) ;
Coves, Juan (Hospital Universitari Son LLàtzer (Palma de Mallorca, Balears)) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Massutí, Bartomeu (Hospital General Universitario de Alicante (Alacant, País Valencià)) ;
Vázquez, Sergio (Hospital Universitario Lucus Augusti (Lugo)) ;
Juan, Óscar (Hospital Universitario y Politécnico La Fe) ;
Collazo-Lorduy, Ana (Hospital Universitario Puerta de Hierro Majadahonda (Madrid)) ;
Gozálvez, Clara L. (Hospital Universitari Sant Joan de Reus (Tarragona)) ;
Barco, Edel D. (Hospital Clínico Universitario (Salamanca)) ;
Rosero, Adriana (Hospital Universitario Infanta Cristina) ;
Bosch-Barrera, J. (Institut Català d'Oncologia) ;
Moreno, María A. (Hospital Universitario de Puerto Real (Cadis)) ;
Mielgo-Rubio, X. (Hospital Universitario Fundación Alcorcón) ;
Villa, J.C. (Hospital General Universitario Ciudad Real) ;
López-Martin, A. (Hospital Universitario Severo Ochoa) ;
Córdoba Ortega, Juan Felipe (Hospital Universitario Arnau de Vilanova) ;
de Asís Aparisi, F. (Hospital General Universitario de Valencia) ;
Zafra, M. (Hospital General Universitario Morales Meseguer (Múrcia)) ;
Mosquera, J. (Complejo Hospitalario Universitario de A Coruña) ;
Altozano, J.P. (Hospital Virgen de los Lirios) ;
Nadal, E. (Institut Català d'Oncologia. Hospitalet de Llobregat) ;
Catot, S. (Altaia. Xarxa Assistencial Universitaria Manresa) ;
Balsalobre, J. (Hospital General Universitario Santa Lucia Cartagena) ;
de Portugal, T. (Complejo Hospitalario de Zamora) ;
Martín, P. (Hospital Clínic Universitari (València)) ;
de Juan, S.C. (Laboratorio Central) ;
Cobo, M. (Hospital Universitario Regional de Málaga) ;
Universitat Autònoma de Barcelona
At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. [...]
2022 - 10.21037/tlcr-21-504
Translational Lung Cancer Research, Vol. 11 Núm. 1 (january 2022) , p. 53-63
|
|
|
9.
|
|
16 p, 2.1 MB |
Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies : a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
/
Grávalos, Cristina (Hospital Universitario 12 de Octubre (Madrid)) ;
Sanmartín, O. (Fundació Institut Valencià d'Oncologia) ;
Gúrpide, A. (Clínica Universidad de Navarra) ;
España, A. (Clínica Universidad de Navarra) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Suh Oh, H.J. (Complejo Hospitalario Universitario de Pontevedra) ;
Aragón, I. (Complejo Hospitalario Universitario de Huelva) ;
Segura, S. (Hospital del Mar (Barcelona, Catalunya)) ;
Beato, C. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Botella, R. (Instituto de Investigación Sanitaria La Fe) ;
Universitat Autònoma de Barcelona
Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth (targeted therapies) or intended to modulate the immune system (immunotherapy). [...]
2019 - 10.1007/s12094-018-1953-x
Clinical & Translational Oncology, Vol. 21 Núm. 5 (january 2019) , p. 556-571
|
|
|
10.
|
|
7 p, 777.8 KB |
SEOM clinical guidelines on nutrition in cancer patients (2018)
/
de las Peñas, Ramon (Consorci Hospitalari Provincial de Castelló) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Perez-Altozano, J. (Hospital Virgen de los Lirios) ;
Virizuela, J.A. (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Cancer, E. (Hospital Universitario de Fuenlabrada ( Madrid)) ;
Diz Taín, P (Hospital Universitario de León) ;
Donnay, O. (Hospital Universitario de la Princesa (Madrid)) ;
Hurtado, A. (Hospital Universitario Fundación Alcorcón) ;
Jimenez-Fonseca, P. (Hospital Universitario Central de Asturias) ;
Ocon, M.J. (Hospital Clínico Universitario "Lozano Blesa" de Zaragoza) ;
Universitat Autònoma de Barcelona
Nutritional deficiency is a common medical problem that affects 15-40% of cancer patients. It negatively impacts their quality of life and can compromise treatment completion. Oncological therapies, such as surgery, radiation therapy, and drug therapies are improving survival rates. [...]
2019 - 10.1007/s12094-018-02009-3
Clinical & Translational Oncology, Vol. 21 Núm. 1 (25 2019) , p. 87-93
|
|
visitante ::
identificación
alerta personal vía correo electrónico o subscríbase al 
canal RSS.
